D-Peptide Mimotopes for Stable Platelet Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mimotopes for inhibiting platelet adhesion and aggregation have limitations in pharmacological compatibility and efficacy, and there is a need for more advanced antithrombotic technologies that can address platelet-related thrombotic issues effectively.
Innovation Solution
Development of peptide mimotopes that mimic the shape and function of platelet integrins and their ligands, which can act as either inhibitors or synthetic receptors when attached to carriers, providing a new class of antithrombotic drugs with enhanced stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural ligands or proteins are used to inhibit platelet adhesion and aggregation, then they can effectively bind to platelet receptors, but they are susceptible to proteolytic degradation and rapid excretion, limiting their pharmacological compatibility and duration of action
Solution Approach 1:
The patent changes the chemical parameters of the ligand by using D-amino acids instead of L-amino acids in the peptide sequence. This parameter change makes the peptide resistant to proteolytic degradation by natural enzymes while maintaining its ability to bind to platelet receptors, thereby extending its duration of action in circulation
Solution Approach 2:
The patent creates a composite structure by conjugating the D-peptide to a carrier molecule (such as albumin or other large molecules). This composite approach provides dual benefits: the D-peptide portion maintains receptor binding specificity while the carrier portion protects against degradation and extends circulation half-life through reduced renal clearance
2Stability of the object's composition
If small peptides are used as mimotopes, then they can resist proteolytic degradation, but they are rapidly excreted by the kidneys due to their small size, limiting their duration of action
Solution Approach 1:
The patent merges the small stable D-peptide with a larger carrier molecule through conjugation. This combining approach allows the small peptide to maintain its proteolytic stability while the large carrier prevents rapid renal excretion, thereby extending the circulation half-life and duration of action of the overall molecule
3Reliability
If existing mimotope inhibitors are used, then they can inhibit platelet adhesion and aggregation, but they have limitations in pharmacological compatibility and require further advancement for effective antithrombotic therapy
Solution Approach 1:
The patent changes the stereochemical parameter of the peptide from L-amino acids to D-amino acids, which fundamentally alters the pharmacological properties. This change provides resistance to proteolytic degradation while maintaining receptor binding affinity, thereby improving both antithrombotic efficacy and pharmacological compatibility for clinical use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide mimotopes effectively inhibit platelet-receptor interactions, offering a new class of antithrombotic drugs that resist proteolytic degradation and excretion, and can be used to treat thrombocytopenia and limit thrombosis, with potential applications in creating synthetic platelets for transfusions.
Implementation Method 1
Mimotopes (mimetics or mimics) are molecules that mimic the function of other, naturally-occurring molecules by virtue of having the same shape (topography) and size as a fragment of/or of the interacting region of naturally-occurring molecules that they are mimicking
Data Source
AI summary
It is provided mimotope receptors and inhibitors that employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, such as liposomes, to act as synthetic platelets, for example, by providing multiple binding sites for binding to other (natural or synthetic) platelets or to the endothelium. Synthetic platelets would have virtually limitless shelf life and would not require disease screening prior to transfusion, thereby providing a solution to the perpetual platelet shortages, as well as the safety and storage issues associated with natural blood platelets.